SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).

Authors

Howard Jack West

Swedish Cancer Institute, Seattle, WA

Howard Jack West , James Moon , Fred R. Hirsch , Philip C Mack , Antoinette J. Wozniak , Derick Lau , Louis Fehrenbacher , Martin Joseph Bury , Mary Weber Redman , David R. Gandara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).

First Author: Joel W. Neal

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).

First Author: Nasser H. Hanna

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Exonic expression variations of EGFR and KRAS in small bronchoscopic biopsies from patients with advanced non-small cell lung cancer treated by combined bevacizumab/erlotinib therapy followed by platinum-based chemotherapy at disease progression: A multicenter phase II trial SAKK19/05.

First Author: M. H. Brutsche

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A randomized phase II study comparing erlotinib with or without bevacizumab in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutation.

First Author: Youngjoo Lee